Pre-conference workshop: Visual mismatch negativity
Tuesday, Sep 8, 2015
Visual mismatch negativity in clinical use
1Pathological Physiology, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
2University of Tartu, Estonia
Continuing systematic exploration of the mismatch negativity in visual domain (vMMN) (93 PubMed entries, March 2015) rose an interest in using of the vMMN for clinical research. Thirty three studies searched for the vMMN alterations among populations of different age (8 studies), or in developmental disorders like autism, dyslexia, mental retardation (6), neurodegenerative disorders (Alzheimer disease, spinocerebellar ataxia, and mild cognitive impairment) (5), mood disorders (4), substance abuse (4), and schizophrenia or schizoaffective disorders (3), panic disorder (1), deafness (1), and hypertension (1). The vMMN successfully discriminated among clinical conditions in thirty studies, it was not altered only in three studies. A meta-analysis showed that a median of the effect size was 0.94 (e.g., large effect). Part of studies (16) also explored a relationship of the vMMN to various clinical markers. The relationship was significant in 10 cases. During the first part of the workshop we will review how the contemporary studies support a prosperity of the vMMN concept in clinical research. Beside diverse clinical conditions also experimental designs varied across studies in the deviance encoding (location, duration, color, motion, shape, face, or emotion), a way of statistical processing, a scalp localization, or a vMMN time interval, which increases possibility of a false positive finding. In the second part of the workshop we will concentrate on necessity of replication studies from independent labs, and standardization of the vMMN examination/evaluation to support inter-laboratory comparisons.